Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology and Surveillance

In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015

Krystyna M. Kazmierczak, Patricia A. Bradford, Gregory G. Stone, Boudewijn L. M. de Jonge, Daniel F. Sahm
Krystyna M. Kazmierczak
aInternational Health Management Associates, Inc., Schaumburg, Illinois, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia A. Bradford
bAstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Patricia A. Bradford
Gregory G. Stone
bAstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boudewijn L. M. de Jonge
bAstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel F. Sahm
aInternational Health Management Associates, Inc., Schaumburg, Illinois, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00592-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Enterobacteriaceae producing the Ambler class D OXA-48 carbapenemase, combined with additional resistance mechanisms, such as permeability defects or cocarriage of class A, B, or C β-lactamases, can become highly resistant to most β-lactams currently in use, including carbapenems. A total of 45,872 Enterobacteriaceae clinical isolates collected in 39 countries as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance study in 2012 to 2015 were tested for susceptibility to β-lactams and comparator agents using the Clinical and Laboratory Standards Institute broth microdilution methodology and screened for the presence of β-lactamases. The blaOXA-48 and blaOXA-48-like genes were detected in 333 isolates across 14 species of Enterobacteriaceae collected in 20 countries across the globe. Few agents tested were effective in vitro against the overall collection of OXA-48-producers (n = 265), with tigecycline (MIC90, 2 µg/ml; 92.5% susceptible), ceftazidime-avibactam (MIC90, 4 µg/ml; 92.5% susceptible), and aztreonam-avibactam (MIC90, 0.5 µg/ml; 99.6% of isolates with MIC ≤8 µg/ml) demonstrating the greatest activity. Similarly, colistin (MIC90, 1 µg/ml; 94.2% susceptible), tigecycline (MIC90, 2 µg/ml; 92.6% susceptible), ceftazidime-avibactam (MIC90, >128 µg/ml; 89.7% susceptible), and aztreonam-avibactam (MIC90, 4 µg/ml; 100% of isolates with MIC ≤8 µg/ml) were most active against OXA-48-like-positive isolates (n = 68). The in vitro activity of ceftazidime-avibactam was improved against the subset of metallo-β-lactamase (MBL)-negative, OXA-48- and OXA-48-like-positive isolates (99.2% and 100% susceptible, respectively). The data reported here support the continued investigation of ceftazidime-avibactam and aztreonam-avibactam for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae carrying OXA-48 and OXA-48-like β-lactamases in combination with serine- or metallo-β-lactamases.

INTRODUCTION

Carbapenem-resistant Enterobacteriaceae cause a high health care burden in hospital and community settings and are globally recognized as threats to the continued utility and efficacy of our existing antimicrobial armamentarium (1, 2). Resistance to carbapenems can be mediated by the production of carbapenemases of Ambler class A (KPC, GES, NMC/IMI, and SME), class B (metallo-β-lactamases [MBL], NDM, VIM, IMP, SPM, and GIM), or class D (OXA-23, OXA-24, OXA-48, OXA-58, and related enzymes), or the hyperproduction of class C cephalosporinases (AmpC) or class A extended-spectrum β-lactamases (ESBLs) coupled with defects in membrane permeability; each of these resistance mechanisms poses a different challenge to treatment (3–8).

OXA-48 hydrolyzes oxacillin, penicillins, and cephalothin, displays poor activity against extended-spectrum cephalosporins (e.g., cefotaxime, ceftazidime, cefepime, and cefpirome) and monobactams (aztreonam), and is poorly inhibited by classic β-lactamase inhibitors, such as clavulanic acid and tazobactam (7, 9). Although it demonstrates greater catalytic activity (kcat/Km) for imipenem than other OXA-type β-lactamases (7), OXA-48 is a weak carbapenemase that often does not confer resistance to carbapenems unless combined with permeability defects (9–13), making it difficult to detect in clinical settings (5, 8). blaOXA-48 is located within a composite Tn1999-type transposon (9) inserted in a self-conjugative, epidemic, broad-host-range IncL/M-type plasmid (pOXA-48a) (11, 14) with high transfer efficiency among Enterobacteriaceae species (15), and it has also been found integrated into the chromosome of Escherichia coli isolates (16, 17). pOXA-48a carries no additional resistance markers; however, as many as 80% of OXA-48-positive isolates are reported to coproduce ESBLs, either through acquisition of additional resistance plasmids or via cocarriage of CTX-M-15 in the mosaic Tn1999.4 transposon (18, 19). In addition, coproduction of OXA-48 and NDM- and VIM-type MBLs has been reported (20–22). OXA-48-producing Enterobacteriaceae were first identified in Turkey and later in North African countries (Morocco, Algeria, Tunisia, Egypt, and Libya), and these areas are considered the main reservoirs of this resistance mechanism (11, 23, 24). However, OXA-48-positive isolates soon spread to countries in the Mediterranean area and have now disseminated throughout much of Europe (5, 6, 25).

Closely related OXA-48-like β-lactamases have also been described. The majority of these display susceptibility profiles similar to that of OXA-48; however, a small number of variants with a four-amino-acid deletion near the enzyme active site (e.g., OXA-163) are able to hydrolyze extended-spectrum cephalosporins and possess attenuated carbapenemase activity (5, 6, 13, 26–30). The genetic contexts and plasmid replicons associated with OXA-48-like β-lactamases differ from those of OXA-48, as does the geographic distribution of these enzymes, though some, notably OXA-181, appear to be disseminating rapidly (5, 6, 26, 27, 29–33).

Avibactam is a non-β-lactam–β-lactamase inhibitor that reacts with the active-site serine of class A, class C, and some class D β-lactamases. Avibactam is not a traditional suicide inhibitor but rather forms a reversible acyl enzyme that is stable to hydrolysis by most serine β-lactamases (34–37). The spectrum of inhibition of avibactam includes class A penicillinases, ESBLs, including CTX-M-type, inhibitor-resistant TEM variants, and carbapenemases, including KPC. It also inhibits both plasmid and chromosomally mediated class C enzymes, as well as some class D OXA-type enzymes, including OXA-48 (34, 35, 37–40). It does not inhibit class B metallo-β-lactamases that have a catalytic zinc atom in the active site (41). When paired with an extended-spectrum cephalosporin, such as ceftazidime, or aztreonam, avibactam protects its partner β-lactam from inactivation by members of these β-lactamase classes, thereby restoring their efficacy. Ceftazidime-avibactam was recently approved and is highly effective against carbapenem-resistant organisms that do not produce MBLs (42–44). Aztreonam-avibactam is being developed for use against infections caused by MBL-producing Enterobacteriaceae. Although aztreonam is stable to MBL hydrolysis (4), MBL-positive isolates often cocarry aztreonam-hydrolyzing serine β-lactamases. By combining aztreonam with avibactam, the hydrolysis of aztreonam is prevented, thereby restoring its activity (45).

This study reports the distribution of OXA-48- and OXA-48-like-positive Enterobacteriaceae isolates collected from 2012 to 2015 as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program, and it evaluates the in vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and comparator agents against these isolates.

RESULTS

A total of 45,872 Enterobacteriaceae isolates were collected in 39 countries participating in the INFORM global surveillance program in 2012 to 2015 (inclusive). In this collection, 11,408 isolates met the molecular screening criteria, and of these, 265 (0.6% of all Enterobacteriaceae) isolates collected from hospitals in 16 countries carried blaOXA-48 (Fig. 1 and Table 1). Klebsiella pneumoniae was the most commonly identified OXA-48-positive species (n = 212 [80.0%]), followed by Escherichia coli (n = 14 [5.3%]) and Enterobacter cloacae (n = 13 [4.9%]). The remaining ∼10% of OXA-48-positive isolates were scattered in prevalence among 11 additional species (6 Klebsiella oxytoca, 5 Citrobacter freundii, 3 Raoultella planticola, 2 each Enterobacter kobei, Morganella morganii, Raoultella ornithinolytica, and Serratia marcescens, and 1 each Citrobacter braakii, Citrobacter koseri, Enterobacter asburiae, and Proteus mirabilis). Isolates carrying blaOXA-48 were found in all four regions surveyed (Europe, Asia-Pacific, the Middle East-Africa region, and Latin America; isolates from the United States were not included in the study). A total of 93.6% of the isolates (n = 248) were collected in Europe, predominantly in Turkey (6.3% of the isolates collected from this country), Russia (3.1% of the collected isolates), Romania (5.2% of the collected isolates), and Spain (1.2% of the collected isolates); in contrast, the percentage of OXA-48 among all Enterobacteriaceae isolates was <1% for most other countries surveyed (Table 1; see also Table S1 in the supplemental material). Smaller numbers of isolates were collected in the Middle East-Africa region (n = 14 of 265 [5.3%]), Asia-Pacific (n = 2 of 265 [0.8%]), and Latin America (n = 1 of 265 [0.4%]) (Table 1). It should be noted that isolates collected from patients in China and Hong Kong, none of which carried blaOXA-48, were only obtained in 2012 to 2013 and 2012 to 2014, respectively, due to export restrictions of bacterial pathogens imposed in later years. In all countries in which at least two OXA-48-positive isolates were identified, isolates were collected at more than one participating institution, except for Italy. OXA-48-positive pathogens were collected from all infection sources (1.2% of bloodstream isolates, 0.9% of respiratory tract isolates, 0.5% of urinary tract isolates, 0.5% of skin and soft tissue isolates, and 0.3% of intra-abdominal isolates), and 87.5% of isolates were collected from patients more than 48 h after hospital admission, suggesting nosocomial acquisition (Table 2). The corresponding data for 68 additional isolates of K. pneumoniae, E. coli, and E. cloacae carrying OXA-48-like β-lactamases (OXA-181, n = 25; OXA-163, n = 13; OXA-232, n = 12; OXA-244, n = 12; OXA-162, n = 3; OXA-370, n = 2; and OXA-439, n = 1) also found during the course of this study are described in Tables S2 and S3.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Distribution of OXA-48-positive Enterobacteriaceae collected in 2012 to 2015. Countries in which OXA-48-positive isolates were detected were Belgium, Brazil, Denmark, France, Germany, Hungary, Israel, Italy, Kuwait, Nigeria, Romania, Russia, Spain, Thailand, Turkey, and the United Kingdom. Participating countries in which OXA-48-positive isolates were not detected were Argentina, Australia, Austria, Chile, China, Hong Kong, Colombia, the Czech Republic, Greece, Ireland, Japan, Kenya, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, South Africa, South Korea, Sweden, Taiwan, and Venezuela. Countries in which OXA-48-like-positive isolates were detected were Argentina (OXA-163 and OXA-439), Belgium (OXA-181 and OXA-232), Brazil (OXA-370), Greece (OXA-163), Italy (OXA-162), Kenya (OXA-181), Kuwait (OXA-232), Mexico (OXA-163 and OXA-232), Romania (OXA-162 and OXA-163), Russia (OXA-244), Thailand (OXA-181 and OXA-232), and Turkey (OXA-162 and OXA-181).

View this table:
  • View inline
  • View popup
TABLE 1

Geographic and species distribution of 265 OXA-48 positive isolates collected as part of the INFORM global surveillance program in 2012 to 2015a

View this table:
  • View inline
  • View popup
TABLE 2

Body source distribution of 265 OXA-48-positive Enterobacteriaceae isolates collected in 2012 to 2015a

Thirty isolates (11.5%) carried OXA-48 alone or with an original-spectrum β-lactamase (OSBL; includes TEM-1, TEM-2, SHV-1, and SHV-11) that does not impact the susceptibility of either ceftazidime or aztreonam alone. The majority of the isolates expressing OXA-48 also carried additional β-lactamases, including plasmid-encoded ESBLs, AmpC, and MBLs, as well as presumed intrinsic chromosomally encoded AmpC enzymes (Fig. 2 and Tables 3 and 4). A total of 88.7% of OXA-48-positive isolates (n = 235) carried additional β-lactamases capable of hydrolyzing expanded-spectrum cephalosporins or aztreonam (Fig. 2 and Table 3) (46, 47). The most common ESBL encountered was CTX-M-15 (158 isolates), followed by CTX-M-14 (24 isolates) and CTX-M-3 (8 isolates). Twenty-seven isolates of Citrobacter spp., Enterobacter spp., M. morganii, and S. marcescens presumed to harbor intrinsic chromosomally encoded AmpC β-lactamases were OXA-48 positive, whereas acquired DHA-type and CMY-type enzymes were found in 7 isolates of E. coli, K. pneumoniae, and E. cloacae. Notably, 23 isolates carried OXA-48 and an MBL. Of these, 11 K. pneumoniae isolates collected at two medical centers in Romania carried OXA-48, NDM-1, and CTX-M-15, whereas four isolates (3 K. pneumoniae and 1 E. cloacae) collected at one center in Romania carried OXA-48 and NDM-1. Six additional isolates (5 C. freundii and 1 E. cloacae) collected at one medical center in Turkey carried OXA-48 and VIM-31, and two E. cloacae isolates collected at one center in Kuwait carried OXA-48, VIM-4, and CMY-4; one of the two E. cloacae isolates also carried an SHV-12 ESBL (Table 3). No isolates cocarrying OXA-48 and the KPC carbapenemase were identified during this study. The β-lactamase carriage of isolates positive for OXA-48-like variants is described in Table S4; of these, 10 isolates carried additional carbapenemases (NDM-1 and OXA-232, n = 7; KPC-2 and OXA-163, n = 2; KPC-2 and OXA-370, n = 1).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Cocarriage of OXA-48 and other β-lactamases in 265 OXA-48-positive Enterobacteriaceae collected in 2012 to 2015. OSBL, original-spectrum β-lactamase unable to hydrolyze extended-spectrum cephalosporins (includes TEM-1, TEM-2, SHV-1, and SHV-11); ESBL, extended-spectrum β-lactamase; AmpC, chromosomal- or plasmid-encoded Ambler class C cephalosporinase; MBL, metallo-β-lactamase. β-Lactamases detected in isolates cocarrying OXA-48 and ESBLs (n) were CTX-M-15 (135), CTX-M-14 (19), CTX-M-3 (8), CTX-M-55 (7), CTX-M-28 (4), CTX-M-24 (2), CTX-M-27 (2), CTX-M-type (2), CTX-M-14 and CTX-M-27 (1), CTX-M-15 and CTX-M-14 (2), and CTX-M-15 and SHV-12 (1). Six isolates were assumed to carry the intrinsic ESBL common to K. oxytoca with CTX-M-14 and CTX-M-27 (1) or without (5) additional acquired ESBLs. β-Lactamases detected in isolates cocarrying OXA-48 and AmpC β-lactamases (n) were intrinsic AmpC β-lactamases common to Citrobacter spp. (2), Enterobacter spp. (7), M. morganii (1), and S. marcescens (1). β-Lactamases detected in isolates cocarrying OXA-48 and AmpC β-lactamases and ESBLs (n) were DHA-1 and CTX-M-15 (3), CMY-6 and CTX-M-15 (1), CMY-42 and CTX-M-15 (1), the intrinsic AmpC common to Enterobacter spp. and CTX-M-15 (3) or CTX-M-9 (1) or SHV-12 (1), the intrinsic AmpC common to M. morganii and CTX-M-15 and CTX-M-14 (1), and the intrinsic AmpC common to S. marcescens and CTX-M-22 (1). β-Lactamases detected in isolates cocarrying OXA-48 and MBLs with or without additional β-lactamases (n) were NDM-1 (3), NDM-1 and CTX-M-15 (11), VIM-31 and the intrinsic AmpC common to Citrobacter spp. (5), NDM-1 (1) or VIM-31 (1) or VIM-4 and CMY-4 (1) or VIM-4, CMY-4, and SHV-12 (1), and the intrinsic AmpC common to Enterobacter spp.

View this table:
  • View inline
  • View popup
TABLE 3

Cocarriage of OXA-48 and other β-lactamases in Enterobacteriaceae isolates collected in 2012 to 2015a

The in vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and comparator agents were determined against the overall collection of Enterobacteriaceae isolates and subsets of OXA-48-positive isolates cocarrying Ambler class A, B, and C β-lactamases (Table 4). The activities of most tested β-lactams, including ceftazidime, aztreonam, cefepime, meropenem, imipenem, and piperacillin-tazobactam, were greatly reduced against the overall collection of OXA-48-positive isolates and against most subsets of isolates cocarrying additional β-lactamases. The percentages of susceptibility to meropenem ranged from 0 to 36.4% and were consistently higher than susceptibilities to imipenem (range, 0 to 11.1% susceptible) among all OXA-48-positive isolates and among subsets of isolates that did not carry MBLs, in agreement with the known hydrolytic properties of OXA-48. The percentages of susceptibility to ceftazidime, aztreonam, and cefepime were <22% for all OXA-48-positive isolates (reflective of the high proportion of isolates cocarrying ESBLs) as well as for ESBL-containing subsets. Percentages of susceptibility to these expanded-spectrum cephalosporins and aztreonam were higher for subsets of isolates carrying OXA-48 alone or in combination with OSBLs that are not expected to have significant activity against these agents or AmpC β-lactamases (73.9 to 100% susceptible). A combination of avibactam with ceftazidime or aztreonam increased the activities of these two β-lactams against all OXA-48-positive isolates by at least 64- and 512-fold, respectively. The MIC90 values for ceftazidime-avibactam and ceftazidime were 4 and >128 µg/ml, respectively, against all OXA-48-positive isolates and 1 and >128 µg/ml, respectively, against the set of OXA-48-positive, MBL-negative isolates (n = 242), whereas the MIC90 values for aztreonam-avibactam and aztreonam were 0.5 and >128 µg/ml, respectively, against all and MBL-negative, OXA-48-positive isolates. Notably, the MIC90 of aztreonam-avibactam against OXA-48-positive isolates coproducing MBLs (n = 23) was 0.5 µg/ml and, as expected, ceftazidime-avibactam showed greatly reduced activity against these isolates (MIC90, >128 µg/ml; 21.7% susceptible). Both aztreonam-avibactam and ceftazidime-avibactam retained good activity against subsets of isolates expressing multiple classes of β-lactamases, including those that produced ESBLs and AmpC β-lactamases in addition to OXA-48. For these strains, the MIC90 values for aztreonam-avibactam and ceftazidime-avibactam were 8 and 4 µg/ml, respectively. The activities of agents from other drug classes (amikacin, tigecycline, and colistin) against OXA-48-positive, MBL-negative isolates were comparable to or reduced compared to the activity of ceftazidime-avibactam (76.1 to 92.6% susceptible) and exceeded it against MBL-positive isolates (34.8 to 100% susceptible). Amikacin, tigecycline, and colistin were less active than aztreonam-avibactam, based on MIC90 values, against all OXA-48-producing subsets except for isolates cocarrying AmpC and ESBL β-lactamases (MIC90, 2 µg/ml and 8 µg/ml for tigecycline and aztreonam-avibactam, respectively) (Table 4).

View this table:
  • View inline
  • View popup
TABLE 4

In vitro activity of antimicrobial agents tested against OXA-48-producing isolates collected in 2012 to 2015

Only two of the OXA-48-positive, MBL-negative isolates were not susceptible to ceftazidime-avibactam (MIC, >8 µg/ml). One carbapenem-nonsusceptible K. pneumoniae isolate carrying OXA-48 and an SHV-OSBL, collected in Hungary, had a ceftazidime-avibactam MIC of 16 µg/ml and aztreonam-avibactam MIC of 0.5 µg/ml and was susceptible to amikacin and tigecycline. The second isolate, a carbapenem-nonsusceptible S. marcescens isolate collected in Russia, carried OXA-48, CTX-M-22, and an SHV-OSBL, had a ceftazidime-avibactam MIC of 64 µg/ml and aztreonam-avibactam MIC of 16 µg/ml, and was resistant to amikacin and tigecycline. The susceptibilities of these two isolates to colistin were not determined. All except one of the OXA-48-positive isolates had an MIC of ≤8 µg/ml to aztreonam-avibactam. This isolate, an S. marcescens strain cocarrying OXA-48, CTX-M-22, and an SHV-OSBL, was also resistant to ceftazidime-avibactam and other classes of agents, as described above.

The activities of ceftazidime-avibactam and aztreonam-avibactam were also evaluated against the OXA-48-like-producing isolates collected during the course of the study (Table 5). Ceftazidime-avibactam MIC90 values against all and MBL-negative isolates were >128 µg/ml (with 89.7% of the isolates testing as susceptible) and 4 µg/ml (with 100% of the isolates testing as susceptible), respectively, and ranged from 1 µg/ml to 4 µg/ml against subsets of MBL-negative isolates carrying individual OXA sequence variants. In comparison, aztreonam-avibactam MIC90s were 4 µg/ml against all and MBL-negative OXA-48-like-positive isolates and ranged from 0.25 µg/ml to 8 µg/ml against individual OXA-48-like variants. All MBL-negative isolates had MIC values of ≤8 µg/ml for both agents.

View this table:
  • View inline
  • View popup
TABLE 5

In vitro activity of antimicrobial agents tested against isolates producing OXA-48-like β-lactamases collected in 2012 to 2015

Higher MIC90 values for both ceftazidime-avibactam and aztreonam-avibactam were observed against 25 OXA-181-producing isolates (4 µg/ml and 8 µg/ml, respectively). This subset of isolates was composed of seven K. pneumoniae isolates with ceftazidime-avibactam MICs of ≤2 µg/ml and aztreonam-avibactam MICs of ≤0.5 µg/ml collected in three countries and 18 E. coli isolates with ceftazidime-avibactam MICs ranging from 1 to 8 µg/ml and aztreonam-avibactam MICs from 4 to 8 µg/ml, 17 of which were collected from one hospital in Turkey over an 11-week period in 2015 (Table S5). Sequencing of the gene encoding penicillin binding protein 3 (pbp3) in a selection of these E. coli isolates revealed a duplication resulting in the insertion of the four-amino-acid sequence YRIN after residue 333 in PBP3 (Table S5). In light of this finding, the pbp3 gene was sequenced in five additional isolates, with four isolates having aztreonam-avibactam MICs of 4 to 16 µg/ml carrying OXA-48 (n = 3) or OXA-163 (n = 1) and one isolate with an MIC of 2 µg/ml carrying OXA-232 (Table S6). The PBP3 YRIN insertion was found in one OXA-48-positive E. coli isolate, which was collected from the same hospital in Turkey as the OXA-181-positive E. coli isolates described in Table S5. No insertions or major sequence alterations in pbp3 were found in the other four isolates screened (two K. pneumoniae, one E. cloacae, and one S. marcescens isolate; Tables S6 and S7).

DISCUSSION

In this report, the incidence, distribution, and antimicrobial susceptibilities of a large set of blaOXA-48-carrying clinical isolates of Enterobacteriaceae collected globally were determined during a recent 4-year period. Although the INFORM surveillance program was not structured to determine the prevalence of organisms carrying specific antimicrobial resistance mechanisms, the findings of this study are in general agreement with those reported by others. The majority (239/265 [90.2%]) of OXA-48-positive isolates were found to be K. pneumoniae, E. coli, and E. cloacae, with dissemination to the greatest number of additional species observed among isolates from Turkey, one of the main reservoirs of blaOXA-48 (5, 6). A total of 64.9% (172/265) of all OXA-48-positive isolates were collected in countries in which endemic (Turkey), interregional (Belgium, France, Romania, and Spain), or regional (Germany and Italy) spread of OXA-48 was recently reported (25, 48, 49). An additional 27.5% (73/265) of isolates were collected from multiple medical centers in Russia; though limited information regarding the epidemiology of carbapenemase-producing Enterobacteriaceae is available for this country, presumed interspecies and interpatient spread of blaOXA-48 was reported during a 2-year period in a hospital intensive care unit located in Moscow (50). Several outbreaks of organisms producing OXA-48 have been noted in European hospitals, most notably in Belgium and the Netherlands where, in general, resistance remains fairly low (51, 52). In this study, a small percentage (0.8%) of the isolates from Belgium harbored OXA-48. These results confirm those of a previous survey in Belgium that showed a consistent low-level incidence of OXA-48 (53). None of the isolates from the Netherlands were positive for OXA-48 in the present study, which correlates with the reported successful infection control measures taken to stop the outbreak in that country (54). Isolates carrying OXA-48-like β-lactamases were found mostly in countries where they had been previously reported (OXA-162, Turkey [55]; OXA-163, Argentina [26]; OXA-181, Belgium, Romania, and Thailand [6, 56, 57]; OXA-232, Mexico and Thailand [56, 58]; OXA-244, Russia [50]; and OXA-370, Brazil [31]). The detection of OXA-162, OXA-163, and OXA-232 in previously undocumented areas may reflect travel by infected individuals or dissemination by other routes.

It should be noted that most likely, this study underreported the number of OXA-48- and OXA-48-like-producing isolates collected in 2012 to 2015 for several reasons. OXA-48 displays higher catalytic activity for imipenem and ertapenem than for meropenem, and isolates that do not harbor additional permeability defects can test as susceptible to one or more, or even all, carbapenems (4, 5, 9–12, 19). Ertapenem, the carbapenem most susceptible to OXA-48 activity, was tested against isolates collected in 2012 and 2013 and removed from the panel in later years. Additionally, the β-lactamase screening criteria were altered in 2015 to exclude the characterization of isolates that tested as imipenem or doripenem nonsusceptible but meropenem susceptible. Although the majority of OXA-48- and OXA-48-like-producers cocarry an ESBL and isolates resistant to ceftazidime (MIC, >8 µg/ml) were also screened for β-lactamase genes, some meropenem-susceptible isolates that did not cocarry ceftazidime-hydrolyzing β-lactamases could also have been omitted from this analysis (5, 12, 19). Finally, due to its insensitivity to inhibition by clavulanic acid, OXA-48-positive isolates rarely test as phenotypically ESBL positive by combination testing. Another limitation is that sequence typing and/or plasmid typing to determine strain relatedness were not assessed.

Ceftazidime-avibactam and aztreonam-avibactam showed good activity against OXA-48- and OXA-48-like producing isolates. Comparable susceptibility results have been reported by others. Livermore et al. obtained MIC90 values of 1 µg/ml (range, 0.06 to 1 µg/ml) for ceftazidime-avibactam and 0.5 µg/ml (range, ≤0.03 to 0.5 µg/ml) for aztreonam-avibactam against 19 isolates of OXA-48-positive K. pneumoniae (41). Vasoo et al. also tested both agents and reported MIC90 values of 4 µg/ml (range, ≤0.06 to >512 µg/ml) for ceftazidime-avibactam and 1 µg/ml (range, ≤0.06 to 1 µg/ml) for aztreonam-avibactam against 14 isolates (12 K. pneumoniae complex, 1 E. coli, and 1 C. koseri) carrying OXA-48 (n = 8), OXA-181 (n = 4), and OXA-232 (n = 2) β-lactamases (59). Sader et al. obtained an aztreonam-avibactam MIC90 value of 0.25 µg/ml (range, ≤0.03 to 0.5 µg/ml) against 57 isolates carrying OXA-48-like β-lactamases (OXA-48, n = 55; OXA-244, n = 1; OXA-370, n = 1) (60), and Haidar et al. reported ceftazidime-avibactam MICs of 1 µg/ml against two OXA-48-positive K. pneumoniae isolates (61). Two MBL-negative OXA-48-positive isolates collected as part of this study had MICs of >8 µg/ml to aztreonam-avibactam and/or ceftazidime-avibactam; these isolates may harbor additional resistance mechanisms, such as amino acid substitutions in cocarried ESBLs or AmpC β-lactamases (62, 63) or changes in drug uptake that have been previously reported to impact the activity of β-lactam–avibactam combinations (64). Twenty-one isolates carrying OXA-48, OXA-181 (17 of 18 isolates possibly representing a clonal outbreak), and OXA-163 had aztreonam-avibactam MICs of 4 to 8 µg/ml. The reduced activity is unlikely to be associated with the OXA enzymes and more likely to be due to insertions in PBP3 which are known to cause reduced activity for aztreonam-avibactam (65). Of these 21 isolates, nine E. coli isolates carrying OXA-181 or OXA-48 were found to possess the four-amino-acid-long YRIN insertion in PBP3. The insertion of YRIN or YRIK after position 333, near the β-lactam binding pocket of E. coli PBP3, was reported to decrease susceptibility to ceftazidime by 4- to 8-fold and to aztreonam by 32-fold and resulted in MIC values for aztreonam-avibactam and ceftazidime-avibactam of 4 to 16 µg/ml and 2 to 8 µg/ml, respectively (65). The insertion of a different four-residue sequence (TIPY inserted after position 344) into the PBP3 of E. coli was proposed to account for MIC values of 8 µg/ml observed for ceftaroline-avibactam, ceftazidime-avibactam, and aztreonam-avibactam in a different study (66). No major disruptions in the sequence of pbp3 were identified in the K. pneumoniae, E. cloacae, and S. marcescens isolates sequenced as part of this study, which were assumed to harbor different resistance mechanisms.

It is important to know the local prevalences of OXA-48 and OXA-48-like β-lactamases among clinical isolates so that infections caused by isolates with a higher MIC value for a carbapenem, even if the MIC does not cross the threshold of “resistant,” should be considered for treatment options other than carbapenems. Therapeutic options available for treating infections caused by carbapenem-resistant Enterobacteriaceae are often limited to older agents, often with impaired safety profiles, such as aminoglycosides, tigecycline, fosfomycin, and polymyxins (8); in this light, recent reports of colistin-resistant OXA-48-producing isolates are very concerning (67–70). This study also showed an increased incidence of colistin resistance in OXA-48-producing isolates, with 21.3% of the isolates being nonsusceptible to colistin, compared to only 17% for all Enterobacteriaceae. This trend is in line with an earlier analysis of clinical isolates from the INFORM study (71). Both ceftazidime-avibactam and aztreonam-avibactam retained activity against all of the OXA-48 and OXA-48-like expressing isolates that contained only that enzyme or coproduced it along with other serine-based ESBLs or AmpC enzymes. Aztreonam-avibactam showed good activity against isolates that also harbored a metallo-β-lactamase. These results confirm that these β-lactam–β-lactamase inhibitor combinations may provide utility in their intended purpose of combating β-lactamase-mediated resistance, including that caused by OXA-48 and OXA-48-like enzymes, β-lactamases that have now become a global problem.

MATERIALS AND METHODS

Nonduplicate clinical isolates were collected from patients with intra-abdominal (n = 8,955), urinary tract (n = 13,166), lower respiratory tract (n = 10,009), skin and soft tissue (n = 11,370), bloodstream (n = 2,243; added as an acceptable specimen source in 2014), and other (n = 129) infections from 182 medical centers located in 39 countries in Europe (24,826 isolates collected by 97 laboratories in 19 countries), Asia-Pacific (9,149 isolates collected by 42 laboratories in 9 countries), the Middle East-Africa region (4,232 isolates collected by 17 laboratories in 5 countries), and Latin America (7,665 isolates collected by 26 laboratories in 6 countries) in 2012 to 2015. Investigators were asked to collect a predefined number of isolates of selected bacterial species, regardless of antimicrobial susceptibility; only one isolate was collected per patient. Basic demographic data were collected but were not linked to patient identity or specific antibiotic therapy. The total number of Enterobacteriaceae isolates collected in each country is listed in Table S1.

Isolates were sent to a central laboratory, where the species identification was confirmed by matrix-assisted laser desorption ionization–time of flight mass spectroscopy (MALDI Biotyper; Bruker Daltonics, Billerica, MA, USA). Susceptibility testing was performed by broth microdilution using custom frozen panels prepared in-house. Panel preparation and isolate and quality control testing followed Clinical and Laboratory Standards Institute (CLSI) guidelines (72, 73). Ceftazidime and aztreonam were tested in combination with a fixed concentration of 4 µg/ml avibactam. MICs were interpreted using current CLSI breakpoints for all drugs (73), except tigecycline, for which breakpoints set by the United States Food and Drug Administration (US FDA) (74) were used; colistin, for which current breakpoints set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (75) were used; and aztreonam-avibactam, for which clinical breakpoints have not been assigned.

All Enterobacteriaceae isolates that tested as nonsusceptible to meropenem (MICs, >1 µg/ml; isolates collected in all years), doripenem or imipenem (MICs, >1 µg/ml; isolates collected in 2012 to 2014), or ertapenem (MICs, >0.5 µg/ml; isolates collected in 2012 to 2013), as well as E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis isolates resistant to ceftazidime (MICs, >8 µg/ml) and/or that were positive for extended-spectrum β-lactamase (ESBL) activity by combination clavulanic acid testing (72), were screened for the presence of genes encoding OXA-48-like and other β-lactamases (KPC, NDM, IMP, VIM, SPM, GIM, TEM, SHV, CTX-M, VEB, PER, GES, ACC, ACT, CMY, DHA, FOX, MIR, and MOX) by multiplex PCR, followed by amplification of detected genes using flanking primers and Sanger sequencing of both DNA strands, as described previously (76). Multiplex primers OXA-48-F (5′-GCTTGATCGCCCTCGATT-3′) and OXA-48-R2 (5′-GATTTGCTSSGTRGCCGAAA-3′) (77) were employed to detect genes encoding OXA-48-like β-lactamases.

ACKNOWLEDGMENTS

We gratefully acknowledge the contributions of the study investigators, laboratory personnel, and all members of the AstraZeneca INFORM Surveillance program.

This study was sponsored by AstraZeneca Pharmaceuticals LP, which also included compensation fees for manuscript preparation. AstraZeneca’s rights to ceftazidime-avibactam and aztreonam-avibactam were acquired by Pfizer in December 2016. K.M.K., P.A.B., B.L.M.D.J., and G.G.S. wrote and edited the manuscript.

K.M.K. and D.F.S. are employees of IHMA. P.A.B. is the owner of Antimicrobial Development Specialists, LLC. B.L.M.D.J. and G.G.S. are employees of Pfizer. None of the IHMA authors has a personal financial interest in the sponsor of this paper (AstraZeneca Pharmaceuticals). P.A.B., B.L.M.D.J., and G.G.S. were employees of and shareholders in AstraZeneca at the time of the study.

All authors provided analysis input and have read and approved the final manuscript.

FOOTNOTES

    • Received 26 March 2018.
    • Returned for modification 6 June 2018.
    • Accepted 7 September 2018.
    • Accepted manuscript posted online 24 September 2018.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.00592-18.

  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, GA.
  2. 2.↵
    World Health Organization. 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. 2017. (WHO/EMP/IAU/2017.12). World Health Organization, Geneva, Switzerland.
  3. 3.↵
    1. Walsh TR,
    2. Toleman MA,
    3. Poirel L,
    4. Nordmann P
    . 2005. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 18:306–325. doi:10.1128/CMR.18.2.306-325.2005.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Queenan AM,
    2. Bush K
    . 2007. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458. doi:10.1128/CMR.00001-07.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Poirel L,
    2. Potron A,
    3. Nordmann P
    . 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597–1606. doi:10.1093/jac/dks121.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Nordmann P,
    2. Poirel L
    . 2014. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20:821–830. doi:10.1111/1469-0691.12719.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Evans BA,
    2. Amyes SGB
    . 2014. OXA β-lactamases. Clin Microbiol Rev 27:241–263. doi:10.1128/CMR.00117-13.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Perez F,
    2. El Chakhtoura NG,
    3. Papp-Wallace K,
    4. Wilson BM,
    5. Bonomo RA
    . 2016. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother 17:761–781. doi:10.1517/14656566.2016.1145658.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Poirel L,
    2. Heritier C,
    3. Tolun V,
    4. Nordmann P
    . 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15–22. doi:10.1128/AAC.48.1.15-22.2004.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Cuzon G,
    2. Naas T,
    3. Bogaerts P,
    4. Glupczynski Y,
    5. Huang TD,
    6. Nordmann P
    . 2008. Plasmid-encoded carbapenem-hydrolyzing β-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob Agents Chemother 52:3463–3464. doi:10.1128/AAC.00543-08.
    OpenUrlFREE Full Text
  11. 11.↵
    1. Carrër A,
    2. Poirel L,
    3. Yilmaz M,
    4. Akan OA,
    5. Feriha C,
    6. Cuzon G,
    7. Matar G,
    8. Honderlick P,
    9. Nordmann P
    . 2010. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother 54:1369–1373. doi:10.1128/AAC.01312-09.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Dimou V,
    2. Dhanji H,
    3. Pike R,
    4. Livermore DM,
    5. Woodford N
    . 2012. Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. J Antimicrob Chemother 67:1660–1665. doi:10.1093/jac/dks124.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Oueslati S,
    2. Nordmann P,
    3. Poirel L
    . 2015. Heterogeneous hydrolytic features of OXA-48-like β-lactamases. J Antimicrob Chemother 70:1059–1063. doi:10.1093/jac/dku524.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Poirel L,
    2. Bonnin RA,
    3. Nordmann P
    . 2012. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob Agents Chemother 56:559–562. doi:10.1128/AAC.05289-11.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Potron A,
    2. Poirel L,
    3. Nordmann P
    . 2014. Derepressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48. Antimicrob Agents Chemother 58:467–471. doi:10.1128/AAC.01344-13.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Beyrouthy R,
    2. Robin F,
    3. Delmas J,
    4. Gibold L,
    5. Dalmasso G,
    6. Dabboussi F,
    7. Hamze M,
    8. Bonnet R
    . 2014. IS1R-mediated plasticity of IncL/M plasmids leads to the insertion of blaOXA-48 into the Escherichia coli chromosome. Antimicrob Agents Chemother 58:3785–3790. doi:10.1128/AAC.02669-14.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Turton JF,
    2. Doumith M,
    3. Hopkins KL,
    4. Perry C,
    5. Meunier D,
    6. Woodford N
    . 2016. Clonal expansion of Escherichia coli ST38 carrying a chromosomally integrated OXA-48 carbapenemase gene. J Med Microbiol 65:538–546. doi:10.1099/jmm.0.000248.
    OpenUrlCrossRef
  18. 18.↵
    1. Potron A,
    2. Nordmann P,
    3. Rondinaud E,
    4. Jaureguy F,
    5. Poirel L
    . 2013. A mosaic transposon encoding OXA-48 and CTX-M-15: toward pan-resistance. J Antimicrob Chemother 68:476–477. doi:10.1093/jac/dks397.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Potron A,
    2. Poirel L,
    3. Rondinaud E,
    4. Nordmann P
    . 2013. Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill 18:pii=20549. doi:10.2807/1560-7917.ES2013.18.31.20549.
    OpenUrlCrossRef
  20. 20.↵
    1. Zowawi HM,
    2. Sartor AL,
    3. Balkhy HH,
    4. Walsh TR,
    5. Al Johani SM,
    6. AlJindan RY,
    7. Alfaresi M,
    8. Ibrahim E,
    9. Al-Jardani A,
    10. Al-Abri S,
    11. Al Salman J,
    12. Dashti AA,
    13. Kutbi AH,
    14. Schlebusch S,
    15. Sidjabat HE,
    16. Paterson DL
    . 2014. Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf Cooperation Council: dominance of OXA-48 and NDM producers. Antimicrob Agents Chemother 58:3085–3090. doi:10.1128/AAC.02050-13.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Seiffert SN,
    2. Marschall J,
    3. Perreten V,
    4. Carattoli A,
    5. Furrer H,
    6. Endimiani A
    . 2014. Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. 2014. Int J Antimicrob Agents 44:260–262. doi:10.1016/j.ijantimicag.2014.05.008.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Hajjej Z,
    2. Gharsallah H,
    3. Naija H,
    4. Boutiba I,
    5. Labbene I,
    6. Ferjani M
    . 2016. Successful treatment of a carbapenem-resistant Klebsiella pneumoniae carrying blaOXA-48, blaVIM-2, blaCMY-2 and blaSHV with high dose combination of imipenem and amikacin. IDCases 4:10–12. doi:10.1016/j.idcr.2016.01.003.
    OpenUrlCrossRef
  23. 23.↵
    1. Alp E,
    2. Perçin D,
    3. Colakoğlu S,
    4. Durmaz S,
    5. Kürkcü CA,
    6. Ekincioğlu P,
    7. Güneş T
    . 2013. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary university hospital in Turkey. J Hosp Infect 84:178–180. doi:10.1016/j.jhin.2013.03.002.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Lahlaoui H,
    2. Poirel L,
    3. Barguellil F,
    4. Moussa MB,
    5. Nordmann P
    . 2012. Carbapenem-hydrolyzing class D β-lactamase OXA-48 in Klebsiella pneumoniae isolates from Tunisia. Eur J Clin Microbiol Infect Dis 31:937–939. doi:10.1007/s10096-011-1389-5.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Albiger B,
    2. Glasner C,
    3. Struelens MJ,
    4. Grundmann H,
    5. Monnet DL, The European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group
    . 2015. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 20:pii=30062. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2015.20.45.30062.
    OpenUrlCrossRef
  26. 26.↵
    1. Poirel L,
    2. Castanheira M,
    3. Carrër A,
    4. Rodriguez CP,
    5. Jones RN,
    6. Smayevsky J,
    7. Nordmann P
    . 2011. OXA-163, an OXA-48-related class D β-lactamase with extended activity toward expanded-spectrum cephalosporins. Antimicrob Agents Chemother 55:2546–2551. doi:10.1128/AAC.00022-11.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Potron A,
    2. Nordmann P,
    3. Lafeuille E,
    4. Al Maskari Z,
    5. Al Rashdi F,
    6. Poirel L
    . 2011. Characterization of OXA-181, a carbapenem-hydrolyzing class D β-lactamase from Klebsiella pneumoniae. Antimicrob Agents Chemother 55:4896–4899. doi:10.1128/AAC.00481-11.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Stojanoski V,
    2. Chow D-C,
    3. Fryszczyn B,
    4. Hu L,
    5. Nordmann P,
    6. Poirel L,
    7. Sankaran B,
    8. Prasad BVV,
    9. Palzkill T
    . 2015. Structural basis for different substrate profiles of two closely related class D β-lactamases and their inhibition by halogens. Biochemistry 54:3370–3380. doi:10.1021/acs.biochem.5b00298.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Dortet L,
    2. Oueslati S,
    3. Jeannot K,
    4. Tande D,
    5. Naas T,
    6. Nordmann P
    . 2015. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Antimicrob Agents Chemother 59:3823–3828. doi:10.1128/AAC.05058-14.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Potron A,
    2. Poirel L,
    3. Dortet L,
    4. Nordmann P
    . 2016. Characterisation of OXA-244, a chromosomally-encoded OXA-48-like β-lactamase from Escherichia coli. Int J Antimicrob Agents 47:102–103. doi:10.1016/j.ijantimicag.2015.10.015.
    OpenUrlCrossRef
  31. 31.↵
    1. Sampaio JLM,
    2. Ribeiro VB,
    3. Campos JC,
    4. Rozales FP,
    5. Magagnin CM,
    6. Falci DR,
    7. da Silva RCF,
    8. Dalarosa MG,
    9. Luz DI,
    10. Vieira FJ,
    11. Antochevis LC,
    12. Barth AL,
    13. Zavascki AP
    . 2014. Detection of OXA-370, an OXA-48-related class D β-lactamase, in Enterobacter hormaechei from Brazil. Antimicrob Agents Chemother 58:3566–3567. doi:10.1128/AAC.02510-13.
    OpenUrlFREE Full Text
  32. 32.↵
    1. Findlay J,
    2. Hopkins KL,
    3. Loy R,
    4. Doumith M,
    5. Meunier D,
    6. Hill R,
    7. Pike R,
    8. Mustafa N,
    9. Livermore DM,
    10. Woodford N
    . 2017. OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007-2014. J Antimicrob Chemother 72:1340–1349. doi:10.1093/jac/dkx012.
    OpenUrlCrossRef
  33. 33.↵
    1. Lutgring JD,
    2. Zhu W,
    3. de Man TJB,
    4. Avillan JJ,
    5. Anderson KF,
    6. Lonsway DR,
    7. Rowe LA,
    8. Batra D,
    9. Rasheed JK,
    10. Limbago BM
    . 2018. Phenotypic and genotypic characterization of Enterobacteriaceae producing oxacillinase-48-like carbapenemases, United States. Emerg Infect Dis 24:700–709. doi:10.3201/eid2404.171377.
    OpenUrlCrossRef
  34. 34.↵
    1. Bonnefoy A,
    2. Dupuis-Hamelin C,
    3. Steier V,
    4. Delachaume C,
    5. Seys C,
    6. Stachyra T,
    7. Fairley M,
    8. Guitton M,
    9. Lampilas M
    . 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J Antimicrob Chemother 54:410–417. doi:10.1093/jac/dkh358.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Stachyra T,
    2. Pechereau M-C,
    3. Bruneau J-M,
    4. Claudon M,
    5. Frere J-M,
    6. Miossec C,
    7. Coleman K,
    8. Black MT
    . 2010. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-lactamase inhibitor. Antimicrob Agents Chemother 54:5132–5138. doi:10.1128/AAC.00568-10.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Docquier J-D,
    2. Benvenuti M,
    3. Calderone V,
    4. Stoczko M,
    5. Menciassi N,
    6. Rossolini GM,
    7. Mangani S
    . 2010. High-resolution crystal structure of the subclass B3 metallo-β-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. Antimicrob Agents Chemother 54:4343–4351. doi:10.1128/AAC.00409-10.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Ehmann DE,
    2. Jahic H,
    3. Ross PL,
    4. Gu RF,
    5. Hu J,
    6. Kern G,
    7. Walkup GK,
    8. Fisher SL
    . 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663–11668. doi:10.1073/pnas.1205073109.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Coleman K
    . 2011. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol 14:550–555. doi:10.1016/j.mib.2011.07.026.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Stachyra T,
    2. Levasseur P,
    3. Pechereau MC,
    4. Girard AM,
    5. Claudon M,
    6. Miossec C,
    7. Black MT
    . 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64:326–329. doi:10.1093/jac/dkp197.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Ehmann DE,
    2. Jahic H,
    3. Ross PL,
    4. Gu RF,
    5. Hu J,
    6. Durand-Reville TF,
    7. Lahiri S,
    8. Thresher J,
    9. Livchak S,
    10. Gao N,
    11. Palmer T,
    12. Walkup GK,
    13. Fisher SL
    . 2013. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 288:27960–27971. doi:10.1074/jbc.M113.485979.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Livermore DM,
    2. Mushtaq S,
    3. Warner M,
    4. Zhang J,
    5. Maharjan S,
    6. Doumith M,
    7. Woodford N
    . 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390–394. doi:10.1128/AAC.00756-10.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    AstraZeneca Pharmaceuticals. Zavicefta package insert. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf.
  43. 43.↵
    1. de Jonge BLM,
    2. Karlowsky JA,
    3. Kazmierczak KM,
    4. Biedenbach DJ,
    5. Sahm DF,
    6. Nichols WW
    . 2016. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 60:4743–3169. doi:10.1128/AAC.00220-16.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Sader HS,
    2. Castanheira M,
    3. Shortridge D,
    4. Mendes RE,
    5. Flamm RK
    . 2017. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother 61:e01045-17. doi:10.1128/AAC.01045-17.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Kazmierczak KM,
    2. Rabine S,
    3. Hackel M,
    4. McLaughlin RE,
    5. Biedenbach DJ,
    6. Bouchillon SK,
    7. Sahm DF,
    8. Bradford PA
    . 2016. Multiyear, multinational survey of the incidence and global distribution of metallo-β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:1067–1078. doi:10.1128/AAC.02379-15.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Bush K,
    2. Jacoby GA
    . 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969–976. doi:10.1128/AAC.01009-09.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Livermore DM
    . 1995. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Lixandru BE,
    2. Cotar AI,
    3. Straut M,
    4. Usein CR,
    5. Cristea D,
    6. Ciontea S,
    7. Tatu-Chitoiu D,
    8. Codita I,
    9. Rafila A,
    10. Nica M,
    11. Buzea M,
    12. Baicus A,
    13. Ghita MC,
    14. Nistor I,
    15. Tuchiluş C,
    16. Indreas M,
    17. Antohe F,
    18. Glasner C,
    19. Grundmann H,
    20. Jasir A,
    21. Damian M
    . 2015. Carbapenemase-producing Klebsiella pneumoniae in Romania: a six-month survey. PLoS One 10:e0143214. doi:10.1371/journal.pone.0143214.
    OpenUrlCrossRef
  49. 49.↵
    1. Timofte D,
    2. Panzaru CV,
    3. Maciuca IE,
    4. Dan M,
    5. Mare AD,
    6. Man A,
    7. Toma F
    . 2016. Active surveillance scheme in three Romanian hospitals reveals a high prevalence and variety of carbapenemase-producing Gram-negative bacteria: a pilot study, December 2014 to May 2015. Euro Surveill 21:pii=30262. doi:10.2807/1560-7917.ES.2016.21.25.30262.
    OpenUrlCrossRef
  50. 50.↵
    1. Fursova NK,
    2. Astashkin EI,
    3. Knyazeva AI,
    4. Kartsev NN,
    5. Leonova ES,
    6. Ershova ON,
    7. Alexandrova IA,
    8. Kurdyumova NV,
    9. Sazikina SY,
    10. Volozhantsev NV,
    11. Svetoch EA,
    12. Dyatlov IA
    . 2015. The spread of blaOXA-48 and blaOXA-244 carbapenemase genes among Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter spp. isolated in Moscow, Russia. Ann Clin Microbiol Antimicrob 14:46. doi:10.1186/s12941-015-0108-y.
    OpenUrlCrossRef
  51. 51.↵
    1. Glupczynski Y,
    2. Huang TD,
    3. Bouchahrouf W,
    4. Rezende de Castro R,
    5. Bauraing C,
    6. Gerard M,
    7. Verbruggen AM,
    8. Deplano A,
    9. Denis O,
    10. Bogaerts P
    . 2012. Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. Int J Antimicrob Agents 39:168–172. doi:10.1016/j.ijantimicag.2011.10.005.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Potron A,
    2. Kalpoe J,
    3. Poirel L,
    4. Nordmann P
    . 2011. European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone. Clin Microbiol Infect 17:E24–E26. doi:10.1111/j.1469-0691.2011.03669.x.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. De Laveleye M,
    2. Huang TD,
    3. Bogaerts P,
    4. Berhin C,
    5. Bauraing C,
    6. Sacre P,
    7. Noel A,
    8. Glupczynski Y
    . 2017. Increasing incidence of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Belgian hospitals. Eur J Clin Microbiol Infect Dis 36:139–146. doi:10.1007/s10096-016-2782-x.
    OpenUrlCrossRef
  54. 54.↵
    1. Dautzenberg MJ,
    2. Ossewaarde JM,
    3. de Kraker ME,
    4. van der Zee A,
    5. van Burgh S,
    6. de Greeff SC,
    7. Bijlmer HA,
    8. Grundmann H,
    9. Cohen Stuart JW,
    10. Fluit AC,
    11. Troelstra A,
    12. Bonten MJ
    . 2014. Successful control of a hospital-wide outbreak of OXA-48-producing Enterobacteriaceae in the Netherlands, 2009 to 2011. Euro Surveill 19:pii=20723. doi:10.2807/1560-7917.ES2014.19.9.20723.
    OpenUrlCrossRef
  55. 55.↵
    1. Kasap M,
    2. Torol S,
    3. Kolayli F,
    4. Dundar D,
    5. Vahaboglu H
    . 2013. OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem. J Enzyme Inhib Med Chem 28:990–996. doi:10.3109/14756366.2012.702343.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Laolerd W,
    2. Akeda Y,
    3. Preeyanon L,
    4. Ratthawongjirakul P,
    5. Santanirand P
    . 2018. Carbapenemase-producing carbapenem-resistant Enterobacteriaceae from Bangkok, Thailand, and their detection by the Carba NP and modified carbapenem inactivation method tests. Microb Drug Resist 24:1006–1011. doi:10.1089/mdr.2018.0080.
    OpenUrlCrossRef
  57. 57.↵
    1. Glupczynski Y,
    2. Jousset A,
    3. Evrard S,
    4. Bonnin RA,
    5. Huang T-D,
    6. Dortet L,
    7. Bogaerts P,
    8. Naas T
    . 2017. Prospective evaluation of the OKN K-SeT assay, a new multiplex immunochromatographic test for the rapid detection of OXA-48-like, KPC and NDM carbapenemases. J Antimicrob Chemother 72:1955–1960. doi:10.1093/jac/dkx089.
    OpenUrlCrossRef
  58. 58.↵
    1. Torres-Gonzalez P,
    2. Cervera-Hernandez ME,
    3. Niembro-Ortega MD,
    4. Leal-Vega F,
    5. Cruz-Hervert LP,
    6. García-García L,
    7. Galindo-Fraga A,
    8. Martinez-Gamboa A,
    9. Bobadilla-del Valle M,
    10. Sifuentes-Osornio J,
    11. Ponce-de-Leon A
    . 2015. Factors associated to prevalence and incidence of carbapenem-resistant Enterobacteriaceae fecal carriage: a cohort study in a Mexican tertiary care hospital. PLoS One 10:e0139883. doi:10.1371/journal.pone.0139883.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Vasoo S,
    2. Cunningham SA,
    3. Cole NC,
    4. Kohner PC,
    5. Menon SR,
    6. Krause KM,
    7. Harris KA,
    8. De PP,
    9. Koh TH,
    10. Patel R
    . 2015. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli. Antimicrob Agents Chemother 59:7842–7846. doi:10.1128/AAC.02019-15.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Sader HS,
    2. Mendes RE,
    3. Pfaller MA,
    4. Shortridge D,
    5. Flamm RK,
    6. Castanheira M
    . 2018. Antimicrobial activity of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 62:e01856-17. doi:10.1128/AAC.00311-18.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Haidar G,
    2. Clancy CJ,
    3. Chen L,
    4. Samanta P,
    5. Shields RK,
    6. Kreiswirth BN,
    7. Nguyen MH
    . 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00642-17.
  62. 62.↵
    1. Lahiri SD,
    2. Johnstone MR,
    3. Ross PL,
    4. McLaughlin RE,
    5. Olivier NB,
    6. Alm RA
    . 2014. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 58:5704–5713. doi:10.1128/AAC.03057-14.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Winkler ML,
    2. Papp-Wallace KM,
    3. Taracila MA,
    4. Bonomo RA
    . 2015. Avibactam and inhibitor-resistant SHV β-lactamases. Antimicrob Agents Chemother 59:3700–3709. doi:10.1128/AAC.04405-14.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Pagès JM,
    2. Peslier S,
    3. Keating TA,
    4. Lavigne JP,
    5. Nichols WW
    . 2016. Role of the outer membrane and porins in susceptibility of β-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob Agents Chemother 60:1349–1359. doi:10.1128/AAC.01585-15.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Alm RA,
    2. Johnstone MR,
    3. Lahiri SD
    . 2015. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 70:1420–1428. doi:10.1093/jac/dku568.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Zhang Y,
    2. Kashikar A,
    3. Brown CA,
    4. Denys G,
    5. Bush K
    . 2017. Unusual Escherichia coli PBP3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam. Antimicrob Agents Chemother 61:e00389-17. doi:10.1128/AAC.00389-17.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Jayol A,
    2. Poirel L,
    3. Dortet L,
    4. Nordmann P
    . 2016. National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014. Euro Surveill 21:pii=30339. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2016.21.37.30339.
    OpenUrl
  68. 68.↵
    1. Madueño A,
    2. Gonzalez Garcia J,
    3. Fernandez-Romero S,
    4. Oteo J,
    5. Lecuona M
    . 2017. Dissemination and clinical implications of multidrug-resistant Klebsiella pneumoniae isolates producing OXA-48 in a Spanish hospital. J Hosp Infect 96:116–122. doi:10.1016/j.jhin.2017.02.024.
    OpenUrlCrossRef
  69. 69.↵
    1. Beyrouthy R,
    2. Robin F,
    3. Lessene A,
    4. Lacombat I,
    5. Dortet L,
    6. Naas T,
    7. Ponties V,
    8. Bonnet R
    . 2017. MCR-1 and OXA-48 in vivo acquisition in KPC-producing Escherichia coli after colistin treatment. Antimicrob Agents Chemother 61:e02540-16. doi:10.1128/AAC.02540-16.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Huang TD,
    2. Bogaerts P,
    3. Berhin C,
    4. Hoebeke M,
    5. Bauraing C,
    6. Glupczynski Y
    . on behalf of a multicentre study group. 2017. Increasing proportion of carbapenemase-producing Enterobacteriaceae and emergence of a MCR-1 producer through a multicentric study among hospital-based and private laboratories in Belgium from September to November 2015. Euro Surveill 22:pii=30530. doi:10.2807/1560-7917.ES.2017.22.19.30530.
    OpenUrlCrossRef
  71. 71.↵
    1. Bradford PA,
    2. Kazmierczak KM,
    3. Biedenbach DJ,
    4. Wise MG,
    5. Hackel M,
    6. Sahm DF
    . 2016. Correlation of β-lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother 60:1385–1392. doi:10.1128/AAC.01870-15.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards—10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
  73. 73.↵
    Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement. CLSI document M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA.
  74. 74.↵
    Pfizer. 2016. Tigecyl FDA prescribing information. Pfizer, Inc., Collegeville, PA.
  75. 75.↵
    European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters, version 7.1. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf.
  76. 76.↵
    1. Lob SH,
    2. Kazmierczak KM,
    3. Badal RE,
    4. Hackel MA,
    5. Bouchillon SK,
    6. Biedenbach DJ,
    7. Sahm DF
    . 2015. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother 59:3606–3610. doi:10.1128/AAC.05186-14.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Dallenne C,
    2. Da Costa A,
    3. Decre D,
    4. Favier C,
    5. Arlet G
    . 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J Antimicrob Chemother 65:490–495. doi:10.1093/jac/dkp498.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
Krystyna M. Kazmierczak, Patricia A. Bradford, Gregory G. Stone, Boudewijn L. M. de Jonge, Daniel F. Sahm
Antimicrobial Agents and Chemotherapy Nov 2018, 62 (12) e00592-18; DOI: 10.1128/AAC.00592-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
Krystyna M. Kazmierczak, Patricia A. Bradford, Gregory G. Stone, Boudewijn L. M. de Jonge, Daniel F. Sahm
Antimicrobial Agents and Chemotherapy Nov 2018, 62 (12) e00592-18; DOI: 10.1128/AAC.00592-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Enterobacteriaceae
OXA-48
aztreonam-avibactam
ceftazidime-avibactam
surveillance

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596